Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Clinical Treatment and Medication Management of Migraine
share announcement

Clinical Treatment and Medication Management of Migraine

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Clinical Neurology".

Deadline for manuscript submissions: closed (1 August 2021) | Viewed by 7673

Special Issue Editor

Dr. Gaku Yamanaka

E-Mail Website
Guest Editor
Department of Pediatrics and Adolescent Medicine, Tokyo Medical University, 6-7 -1 Nishi Shinjuku, Shinjuku, Tokyo 160-0023, Japan
Interests: migraine; epilepsy; encephalitis/encephalopathy; neuroinflammation; neuroimmunology

Special Issue Information

Dear Colleagues,

Migraine headaches are common in children, adolescents, and adults worldwide and significantly affect patients’ quality of life in a negative way. Although neuroinflammation, disruptions in the descending pain-modulating network, and trigeminal and autonomic system dysfunction are known contributors to the pathogenesis of migraines, their exact roles and the causative mechanisms in this condition remain unclear, and established treatments are currently unavailable.

The therapeutic options for patients with migraine have greatly expanded in recent times; newer medications that target the calcitonin gene-related peptide (CGRP) and neuromodulatory devices are presently available. Notably, a significant placebo effect is observed in patients who receive acute and preventive migraine therapy. Cognitive behavioral therapy (CBT) and nutraceuticals are shown to be useful in patients with migraine. Considering the high incidence of comorbidities in patients, migraine therapy must necessarily involve comprehensive management tailored to the patient, combined with drug therapy. Clinicians should focus on improving patients’ quality of life. Optimal migraine therapy must necessarily include both pharmacological and nonpharmacological approaches.

This Special Issue that discusses “Clinical Treatment and Medication Management of Migraines” aims to update researchers and clinicians by presenting a review of recent advances in targeted therapy in patients with migraine, describing both pharmacological and nonpharmacological therapeutic approaches.

Dr. Gaku Yamanaka
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Migraine
  • CGRP
  • Neuromodulatory devices
  • Headache education
  • CBT
  • Comorbidities
  • Nutraceuticals
  • Placebo effect

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

16 pages, 259 KiB  
Review
Complementary and Integrative Medicines as Prophylactic Agents for Pediatric Migraine: A Narrative Literature Review
by Gaku Yamanaka, Kanako Kanou, Tomoko Takamatsu, Mika Takeshita, Shinichiro Morichi, Shinji Suzuki, Yu Ishida, Yusuke Watanabe, Soken Go, Shingo Oana and Hisashi Kawashima
J. Clin. Med. 2021, 10(1), 138; https://doi.org/10.3390/jcm10010138 - 3 Jan 2021
Cited by 11 | Viewed by 3750
Abstract
Complementary and integrative medicines (CIMs) are increasingly used as a preventive antimigraine therapy. In this review, we aimed to summarize the evidence for the efficacy and safety of eight CIMs (riboflavin, coenzyme Q10, magnesium, melatonin, polyunsaturated fatty acids, and combination therapy of feverfew, [...] Read more.
Complementary and integrative medicines (CIMs) are increasingly used as a preventive antimigraine therapy. In this review, we aimed to summarize the evidence for the efficacy and safety of eight CIMs (riboflavin, coenzyme Q10, magnesium, melatonin, polyunsaturated fatty acids, and combination therapy of feverfew, vitamin D, and ginkgolide B) in pediatric migraine prevention. The level of evidence for riboflavin was relatively high; it was investigated by many studies with five/seven studies demonstrating its efficacy. Five studies investigated the use of melatonin, with one reporting negative results. There was insufficient evidence on the effectiveness of coenzyme Q10, magnesium, and polyunsaturated fatty acids. Combination therapy showed positive potential; however, reports on the individual antimigraine effects of the CIMs were lacking. A definitive conclusion was not reached regarding the specific integrative drugs clinicians should choose for pediatric migraines, owing to low-quality evidence and a limited number of studies. Integrative medications are becoming more common for pediatric migraine prevention as they do not produce serious side effects, and underlying research data suggest their efficacy in preventing migraine. Additional studies are warranted to confirm the role of CIMs in treating patients with migraines. Full article
(This article belongs to the Special Issue Clinical Treatment and Medication Management of Migraine)
14 pages, 473 KiB  
Review
A Review on the Triggers of Pediatric Migraine with the Aim of Improving Headache Education
by Gaku Yamanaka, Shinichiro Morichi, Shinji Suzuki, Soken Go, Mika Takeshita, Kanako Kanou, Yu Ishida, Shingo Oana and Hisashi Kawashima
J. Clin. Med. 2020, 9(11), 3717; https://doi.org/10.3390/jcm9113717 - 19 Nov 2020
Cited by 16 | Viewed by 3465
Abstract
Although migraines are common in children and adolescents, they have a robustly negative impact on the quality of life of individuals and their families. The current treatment guidelines outline the behavioral and lifestyle interventions to correct common causative factors, such as negative emotional [...] Read more.
Although migraines are common in children and adolescents, they have a robustly negative impact on the quality of life of individuals and their families. The current treatment guidelines outline the behavioral and lifestyle interventions to correct common causative factors, such as negative emotional states, lack of exercise and sleep, and obesity; however, the evidence of their effectiveness is insufficient. To create a plan for disseminating optimal pediatric headache education, we reviewed the current evidence for factors correlated with migraine. We assessed three triggers or risk factors for migraines in children and adolescents: stress, sleep poverty, and alimentation (including diet and obesity). While there is a gradual uptick in research supporting the association between migraine, stress, and sleep, the evidence for diet-related migraines is very limited. Unless obvious dietary triggers are defined, clinicians should counsel patients to eat a balanced diet and avoid skipping meals rather than randomly limiting certain foods. We concluded that there is not enough evidence to establish a headache education plan regarding behavioral and lifestyle interventions. Clinicians should advise patients to avoid certain triggers, such as stress and sleep disorders, and make a few conservative dietary changes. Full article
(This article belongs to the Special Issue Clinical Treatment and Medication Management of Migraine)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop